BIIB - Company ID 0000875045
The table below shows BIOGEN INC.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $2.48B | $2.53B | $2.65B | $2.43B | $2.47B | $2.46B |
| Cost of revenue | $661.00M | $674.40M | $605.00M | $629.30M | $638.70M | $546.00M |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
BIOGEN INC. reported annual revenue of $9.89B for fiscal year 2025. That is up 2.2% from $9.68B in fiscal 2024. Over the 10 fiscal years shown, annual revenue declined from $11.45B (FY 2016) to $9.89B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $607.30M |
| $594.80M |
| $583.80M |
| $572.50M |
| $588.40M |
| $553.80M |
| Operating income | - | - | - | - | - | - |
| Income tax | $58.20M | $90.80M | $109.20M | $70.70M | $62.50M | $115.10M |
| Net income | $319.50M | $466.50M | $634.80M | $240.50M | $388.50M | $583.60M |
| EPS (diluted) | $2.15 | $3.17 | $4.33 | $1.64 | $2.66 | $4.00 |